Meridian Bioscience buys GenePOC
September 2019—Meridian Bioscience has acquired Quebec City-–based GenePOC, a provider of molecular diagnostic instruments and assays.
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Quest offers HIV PrEP test services
September 2019—Quest Diagnostics announced the availability of its test panel to guide therapy with HIV pre-exposure prophylaxis, or PrEP. PrEP is the use of antiretroviral drugs to help prevent HIV infection in high-risk individuals who are not infected.
Thermo Fisher previews automated AST system
September 2019—Thermo Fisher Scientific previewed its Sensititre Aris HiQ AST System at the 71st annual AACC meeting. The benchtop automated reading and incubation system for antimicrobial susceptibility testing uses broth microdilution to provide minimum inhibitory concentration results.
FDA permits marketing of prosthetic joint infection test
September 2019—The U.S. Food and Drug Administration permitted marketing of the Synovasure Lateral Flow Test Kit (CD Diagnostics) as an aid for the detection of periprosthetic joint infection in the synovial fluid of patients being evaluated for revision surgery. The test kit detects human alpha defensins in the synovial fluid of patients with a total joint replacement in approximately 10 minutes. The test is not intended to identify a specific type of infection.
Mesa Biotech launches RSV test
September 2019—Mesa Biotech launched its respiratory syncytial virus test, the company’s second point-of-care test on its polymerase chain reaction testing platform, the Accula System, at the AACC annual scientific meeting. The Accula Flu A/Flu B test received FDA clearance in 2018. Both tests are indicated for use with nasal swab collection.
FDA expands use of Vitros HIV Combo test
September 2019—Ortho Clinical Diagnostics announced that its Vitros Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator (Vitros HIV Combo test) has been granted FDA premarket approval for use on Ortho’s Vitros XT 7600 Integrated System. The Vitros HIV Combo is a fourth-generation test that detects HIV-1 and HIV-2 antibodies and the p24 antigen.
MedTest Dx releases new line of calibrators, controls
September 2019—MedTest Dx introduced at the 2019 American Association for Clinical Chemistry annual scientific meeting an improved line of Clinitox Calibrators and Controls for confirmation testing. The product line aims to provide laboratories performing drugs of abuse testing a comprehensive and reliable calibration and controls solution with extended shelf life and simplified documentation.
FDA OKs marketing of first Zika virus antibodies Dx
August 2019—The U.S. Food and Drug Administration authorized marketing of a diagnostic test to detect Zika virus immunoglobulin antibodies in human blood. The ZIKV Detect 2.0 IgM Capture ELISA (InBios, Seattle) is the first Zika diagnostic test the FDA has allowed to be marketed in the U.S.; previously, tests for detecting Zika virus IgM antibodies, including the InBios test, had been authorized only for emergency use.
NeuMoDx launches CE-IVD assays
August 2019—NeuMoDx Molecular launched its CE-IVD assays for hepatitis B virus and hepatitis C virus. The company also launched CE-IVD assays for cytomegalovirus and Epstein-Barr virus.
Binding Site TBE antigens, purified human CRP
August 2019—Binding Site’s Immunologicals Group added two native tick-borne encephalitis viral antigens to its line of products for in vitro diagnostic manufacturing and research applications. The standard version of the antigen as well as the premium version are for use as components in enzyme immunoassay testing procedures.